Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;7(3):279-286.
doi: 10.3233/JHD-189003.

Huntington's Disease Clinical Trials Corner: August 2018

Filipe B Rodrigues  1   2   3 , Edward J Wild  1
Affiliations

Huntington's Disease Clinical Trials Corner: August 2018

Filipe B Rodrigues et al. J Huntingtons Dis. 2018.

Abstract

In the third edition of the Huntington's Disease Clinical Trials Corner we list all currently registered and ongoing clinical trials, expand on the SIGNAL trial (NCT02481674), and cover the recently finished CREST-E trial (NCT00712426).

Keywords: Huntington disease; clinical trials.

PubMed Disclaimer

References

    1. Vaccinex Inc. Huntington Study Group. VX15/2503 Treatment for Huntington's Disease, 2015. https://ClinicalTrials.gov/show/NCT02481674
    1. Hersch SM, Schifitto G, Oakes D, Bredlau A-L, Meyers CM, Nahin R, et al. The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology 2017;89(6):594–601. - PMC - PubMed
    1. Massachusetts General Hospital. Creatine Safety. Tolerabil-ity, & Efficacy in Huntington's Disease (CREST-E), 2008. https://ClinicalTrials.gov/show/NCT00712426
    1. Rodrigues FB, Wild EJ Clinical Trials Corner: September 2017. J Huntingtons Dis 2017;6(3):255–63. - PMC - PubMed
    1. Leonard JE, Fisher TL, Winter LA, Cornelius CA, Reilly C, Smith ES, et al. Nonclinical Safety Evaluation of VX15/a Humanized IgG4 Anti-SEMA4D Antibody. Molecular cancer therapeutics 2015;14(4):964–72. - PubMed

Publication types

Associated data